HK1092711A1 - Pharmeceutical composition with improved solubility and fluidity - Google Patents

Pharmeceutical composition with improved solubility and fluidity

Info

Publication number
HK1092711A1
HK1092711A1 HK06113473A HK06113473A HK1092711A1 HK 1092711 A1 HK1092711 A1 HK 1092711A1 HK 06113473 A HK06113473 A HK 06113473A HK 06113473 A HK06113473 A HK 06113473A HK 1092711 A1 HK1092711 A1 HK 1092711A1
Authority
HK
Hong Kong
Prior art keywords
fluidity
improved solubility
pharmeceutical
composition
pharmeceutical composition
Prior art date
Application number
HK06113473A
Inventor
Hideyoshi Kanbe
Toshiaki Kurazumi
Teiji Murata
Original Assignee
Ssp Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ssp Co Ltd filed Critical Ssp Co Ltd
Publication of HK1092711A1 publication Critical patent/HK1092711A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06113473A 2003-09-05 2006-12-07 Pharmeceutical composition with improved solubility and fluidity HK1092711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003313853A JP4575654B2 (en) 2003-09-05 2003-09-05 Pharmaceutical composition with improved solubility and fluidity
PCT/JP2004/012827 WO2005023222A1 (en) 2003-09-05 2004-09-03 Pharmaceutical composition with improved solubility and fluidity

Publications (1)

Publication Number Publication Date
HK1092711A1 true HK1092711A1 (en) 2007-02-16

Family

ID=34269778

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06113473A HK1092711A1 (en) 2003-09-05 2006-12-07 Pharmeceutical composition with improved solubility and fluidity

Country Status (6)

Country Link
JP (1) JP4575654B2 (en)
KR (1) KR20060119860A (en)
CN (1) CN100389750C (en)
HK (1) HK1092711A1 (en)
TW (1) TWI344376B (en)
WO (1) WO2005023222A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2404939T3 (en) * 2005-06-27 2013-05-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
AU2007319820B2 (en) * 2006-11-13 2013-09-05 Ethicon, Incorporated In vitro expansion of postpartum-derived cells using microcarriers
JP5201819B2 (en) * 2006-11-22 2013-06-05 エスエス製薬株式会社 Solid composition
WO2011108644A1 (en) * 2010-03-03 2011-09-09 ライオン株式会社 Solid pharmaceutical composition and pharmaceutical preparation
CN105343006B (en) * 2015-12-02 2019-05-14 北京大学 A kind of nanometer shell system and its preparation method and application carrying insoluble drug
CN105832680B (en) * 2016-05-12 2018-12-25 沈阳药科大学 A kind of pharmaceutical composition improving spirolactone In Vitro Dissolution and mobility
JP6918392B2 (en) * 2021-01-13 2021-08-11 築野食品工業株式会社 Yield improvement in powder production or generation, scattering or solidification inhibitor of fine powder in powder use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84875A1 (en) * 1983-06-27 1985-03-29 Oreal TINCTORIAL COMPOSITIONS FOR KERATINIC FIBERS BASED ON DIRECT DYES AND XANTHANE GUM
DE3720757A1 (en) * 1987-06-24 1989-01-05 Bayer Ag DHP COAT TABLET
CH675537A5 (en) * 1988-03-25 1990-10-15 Ciba Geigy Ag
JP3037393B2 (en) * 1990-10-22 2000-04-24 大正薬品工業株式会社 Method for producing solid drug for oral administration
AU8913491A (en) * 1990-11-30 1992-06-25 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JP3247511B2 (en) * 1993-09-07 2002-01-15 山之内製薬株式会社 Pharmaceutical composition
JP3096666B2 (en) * 1996-11-01 2000-10-10 藤崎電機株式会社 Method and apparatus for granulating powder
JP3870470B2 (en) * 1997-02-07 2007-01-17 大正製薬株式会社 Multiple unit type sustained release tablets
DE19709663A1 (en) * 1997-03-10 1998-09-17 Basf Ag Use of redispersible polymer powders or polymer granules as binders for the production of solid pharmaceutical dosage forms
JP4063386B2 (en) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 Rapid-release oral pharmaceutical composition
JP4438121B2 (en) * 1998-04-27 2010-03-24 大正製薬株式会社 Intraoral rapidly disintegrating tablet and method for producing the same
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
EP1203580A4 (en) * 1999-06-18 2004-06-30 Takeda Chemical Industries Ltd Quickly disintegrating solid preparations

Also Published As

Publication number Publication date
CN100389750C (en) 2008-05-28
JP2005082503A (en) 2005-03-31
CN1842324A (en) 2006-10-04
KR20060119860A (en) 2006-11-24
TWI344376B (en) 2011-07-01
TW200514571A (en) 2005-05-01
WO2005023222A1 (en) 2005-03-17
JP4575654B2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
HK1080717A1 (en) Pharmaceutical compositions with improved dissolution
EP1654005A4 (en) Stable radiopharmaceutical compositions and methods for preparation
GB0411940D0 (en) Methods and compositions
HK1093975A1 (en) Ppar-activating compound and pharmaceutical composition containing same
EP1701725A4 (en) Methods and compositions
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
HU0301154D0 (en) Pharmaceutical composition
IL183986A0 (en) Pharmaceutical compounds and compositions
IL182126A (en) Compositions containing 5-phenoxyalkoxypsoralen derivatives and uses thereof
GB0300427D0 (en) Pharmaceutical composition
HK1092711A1 (en) Pharmeceutical composition with improved solubility and fluidity
GB0307866D0 (en) Pharmaceutical composition
EP1699458A4 (en) Pharmaceutical composition
GB0329232D0 (en) Pharmaceutical composition
GB0317663D0 (en) Pharmaceutical composition
HK1093896A1 (en) Medicinal composition
IL179669A0 (en) Benzoimidazole derivatives and pharmaceutical compositions containing the same
AU2003267231A8 (en) Pharmaceutical compositions with improved dissolution
EP1600445A4 (en) Medicinal composition
GB0300885D0 (en) Pharmaceutical composition
EP1655029A4 (en) Medicinal compositions
HK1095737A1 (en) Medicinal composition in solution form
GB0306933D0 (en) Pharmaceutical composition
GB0307869D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130903